Dendreon will not receive any proceeds from the sale of the shares of Common Stock in the offering.
The offering of the Notes and of the Common Stock is being led by J.P. Morgan Securities LLC. The Notes and the Common Stock will both be offered and sold under Dendreon's shelf registration statement filed with the Securities and Exchange Commission on December 8, 2009, as amended by a post-effective amendment filed with the Securities and Exchange Commission on January 13, 2011. Before you invest in the Notes or the shares of Common Stock, you should read the prospectus and the preliminary prospectus supplement to that registration statement, as well as the post-effective amendment to that registration statement and other documents that Dendreon has filed with the SEC for more complete information about Dendreon and the offerings. You may get these documents at the SEC web site at www.sec.gov. Printed copies of the preliminary prospectus supplement relating to these offerings may also be obtained by requesting copies from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by calling 1-866-803-9204.
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sales of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any jurisdiction.
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. Dendreon applies its expertise in antigen identification, engineering and cell processing to pr
|SOURCE Dendreon Corporation|
Copyright©2010 PR Newswire.
All rights reserved